Drugs / CD133(+) cells
CD133(+) cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02915796 | Sep 2016 → Apr 2017 | peripheral arterial disease | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD133(+) cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02915796 ↗ |
| Known as | CD 133(+) endothelial progenitor cells | “isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator” NCT02915796 ↗ |
| Known as | CD133+ cell | “CD133+ cell, a bone marrow derived subpopulation of adult hematopoietic progenitor cells, confers high proliferative, vasculogenic and regenerative capacity in vitro and in vivo.” NCT02915796 ↗ |
| Modality | Cell therapy | “received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery” NCT02915796 ↗ |
| Route | Other | “received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery” NCT02915796 ↗ |